Jie Lei, MD; Jinbo Zhao, MD; Li Gong, MD; et al.
open access
JAMA Oncol. 2023;9(10):1348-1355. doi:10.1001/jamaoncol.2023.2751
This randomized clinical trial assesses the efficacy and safety of neoadjuvant camrelizumab plus chemotherapy vs chemotherapy alone for patients with resectable stage IIIA or IIIB non–small cell lung cancer (NSCLC).
Julien Taïeb, MD, PhD; Olivier Bouche, MD, PhD; Thierry André, MD; et al.
open access
JAMA Oncol. 2023;9(10):1356-1363. doi:10.1001/jamaoncol.2023.2761
This randomized clinical trial compares the efficacy and safety of avelumab as a second-line treatment in patients with deficient mismatch repair and/or microsatellite instability (dMMR/MSI) metastatic colorectal cancer (mCRC) who had not been treated previously with immunotherapeutic agents and in whom standard first-line treatment failed with standard second-line treatment.
Benjamin J. Peipert, MD; Nivedita R. Potapragada, BA; Paul M. Lantos, MD, MS; et al.
free access
has audio
JAMA Oncol. 2023;9(10):1364-1370. doi:10.1001/jamaoncol.2023.2780
This cross-sectional study characterizes the distribution of centers offering fertility preservation services in the US and quantifies the number of self-identified reproductive-age female individuals living outside of geographically accessible areas.
-
Podcast:
A Geospatial Analysis of Disparities in Access to Oncofertility Services
Joseph M. Unger, PhD; Hong Xiao, PhD; Riha Vaidya, PhD; et al.
free access
JAMA Oncol. 2023;9(10):1371-1379. doi:10.1001/jamaoncol.2023.2800
This cohort study assesses participation of patients with Medicaid in cancer clinical trials after Patient Protection and Affordable Care Act Medicaid expansion.
-
Invited Commentary
Medicaid Expansion and Clinical Trials—Why Doing the Right Thing Helps Us Do the Best Science
Samilia Obeng-Gyasi, MD, MPH; Oluwadamilola M. Fayanju, MD, MA, MPHS
JAMA Oncol
Jens Huober, MD; Patrik Weder, MD; Karin Ribi, PhD; et al.
free access
JAMA Oncol. 2023;9(10):1381-1389. doi:10.1001/jamaoncol.2023.2909
This secondary analysis of a randomized clinical trial assesses whether trastuzumab plus pertuzumab without chemotherapy is an optimal first-line treatment in patients with metastatic breast cancer.
Shuchi Gulati, MD, MSc; Chih-Yuan Hsu, PhD; Surbhi Shah, MD; et al.
open access
JAMA Oncol. 2023;9(10):1390-1400. doi:10.1001/jamaoncol.2023.2934
This cohort study assesses the association between anticancer therapy exposure and thromboembolic events following COVID-19 diagnosis in patients with cancer.
GBD 2019 Lip, Oral, and Pharyngeal Cancer Collaborators
open access
JAMA Oncol. 2023;9(10):1401-1416. doi:10.1001/jamaoncol.2023.2960
This systematic analysis assesses the total and risk-attributable burden of lip and oral cavity cancer and other pharyngeal cancer for 204 countries and territories and by Socio-demographic Index using 2019 Global Burden of Diseases, Injuries, and Risk Factors Study estimates.
Alexandra L. Potter, BS; Vedha Vaddaraju; Shivaek Venkateswaran; et al.
free access
JAMA Oncol. 2023;9(10):1417-1422. doi:10.1001/jamaoncol.2023.3066
This cross-sectional study examines COVID-19 mortality in patients with cancer compared with the general population during different waves of the pandemic.
Enrui Xie, MD; Yee Hui Yeo, MD; Bernhard Scheiner, MD, PhD; et al.
open access
JAMA Oncol. 2023;9(10):1423-1431. doi:10.1001/jamaoncol.2023.3284
This systematic review and meta-analysis evaluates the efficacy and safety of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma with Child-Pugh class B liver function.